Metabolic profiling identifies lung tumor responsiveness to erlotinib

Experimental and Molecular Pathology

Volumn 87, Issue 1, 2009, Pages 83-86

  Fan, Teresa W M ^a,b,c   Lane, Andrew N ^b,c   Higashi, Richard M ^a,c   Bousamra II, Michael ^c   Kloecker, Goetz ^c   Miller, Donald M ^b,c  

^a UNIVERSITY OF LOUISVILLE   (United States)

^b Center for Regulatory and Environmental Analytical Metabolomics (CREAM)   (United States)

^c University of Louisville School of Medicine   (United States)

Author keywords

Bronchioalveolar adenocarcinoma; Erlotinib; Metabolomics

Indexed keywords

ERLOTINIB; GEFITINIB; PROTEIN TYROSINE KINASE INHIBITOR; TISSUE EXTRACT;

AGED; ARTICLE; ASIAN; CANCER GROWTH; CANCER TISSUE; CASE REPORT; CORRELATION ANALYSIS; DRUG RESPONSE; DRUG SENSITIVITY; FEMALE; HUMAN; LUNG ALVEOLUS CELL CARCINOMA; LUNG LESION; LUNG NON SMALL CELL CANCER; LUNG TUMOR; MASS SPECTROMETRY; METABOLOMICS; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PHOSPHOLIPID METABOLISM; POSITRON EMISSION TOMOGRAPHY; PREVALENCE; PROTEIN METABOLISM; SMOKING;

AGED, 80 AND OVER; ASIAN CONTINENTAL ANCESTRY GROUP; CARCINOMA, NON-SMALL-CELL LUNG; FEMALE; HUMANS; LUNG NEOPLASMS; METABOLOME; POSITRON-EMISSION TOMOGRAPHY; PROTEIN KINASE INHIBITORS; QUINAZOLINES;

EID: 67649446283     PISSN: 00144800     EISSN: 10960945     Source Type: Journal    
DOI: 10.1016/j.yexmp.2009.04.004     Document Type: Article

References (23)

1. Ahmed S.M., and Salgia R. Epidermal growth factor receptor mutations and susceptibility to targeted therapy in lung cancer. Respirology 11 (2006) 687-692
2. Altenberg B., and Greulich K.O. Genes of glycolysis are ubiquitously overexpressed in 24 cancer classes. Genomics 84 (2004) 1014-1020
3. Bhattacharjee A., Richards W.G., Staunton J., Li C., Monti S., Vasa P., Ladd C., Beheshti J., Bueno R., Gillette M., Loda M., Weber G., Mark E.J., Lander E.S., Wong W., Johnson B.E., Golub T.R., Sugarbaker D.J., and Meyerson M. Classification of human lung carcinomas by mRNA expression profiling reveals distinct adenocarcinoma subclasses. Proc. Natl. Acad. Sci. U. S. A. 98 (2001) 13790-13795
4. Brognard J., Clark A.S., Ni Y.C., and Dennis P.A. Akt/protein kinase B is constitutively active in non-small cell lung cancer cells and promotes cellular survival and resistance to chemotherapy and radiation. Cancer Res. 61 (2001) 3986-3997
5. Carretero J., Medina P.P., Blanco R., Smit L., Tang M., Roncador G., Maestre L., Conde E., Lopez-Rios F., Clevers H.C., and Sanchez-Cespedes M. Dysfunctional AMPK activity, signalling through mTOR and survival in response to energetic stress in LKB1-deficient lung cancer. Oncogene 26 (2007) 1616-1625
6. Collaboration T.C. Chemotherapy for Non-small Cell Lung Cancer (2009), John Wiley and Sons, Ltd 1-106 C. Library
7. Fan T.W., and Lane A.N. Structure-based profiling of metabolites and isotopomers by NMR. Prog. Nucl. Magn. Reson. Spectrosc. 52 (2008) 69-117
8. Fan T.W.M., Higashi R.M., Lane A.N., and Jardetzky O. Combined use of H-1-NMR and GC-MS for metabolite monitoring and invivo H-1-NMR assignments. Biochim. Biophys. Acta 882 (1986) 154-167
9. Fan T., Bandura L., Higashi R., and Lane A. Metabolomics-edited transcriptomics analysis of Se anticancer action in human lung cancer cells. Metabolomics 1 (2005) 1-15
10. Fan T.W.M., Higashi R.M., and Lane A.N. Integrating metabolomics and transcriptomics for probing Se anticancer mechanisms. Drug Metab. Rev. 38 (2006) 707-732
11. Garber K. Energy boost: the Warburg effect returns in a new theory of cancer. J. the Natl. Cancer Inst. 96 (2004) 1805-1806
12. Giaccone G., Ruiz M.G., Le Chevalier T., Thatcher N., Smit E., Rodriguez J.A., Janne P., Oulid-Aissa D., and Soria J.C. Erlotinib for frontline treatment of advanced non-small cell lung cancer: a phase II study. Clin. Cancer Res. 12 (2006) 6049-6055
13. Il Na I., Rho J.K., Choi Y.J., Kim C.H., Park J.H., Koh J.S., Ryoo B.Y., Yang S.H., and Lee J.C. The survival outcomes of patients with resected non-small cell lung cancer differ according to EGFR mutations and the P21 expression. Lung Cancer 57 (2007) 96-102
14. Kris M.G., Giaccone G., Davies A., Fukuoka M., Garfield D.H., Jassem J., Quoix E.A., Sandler A.B., Scagliotti G.V., Van Meerbeeck J.P., and West H. Systemic therapy of bronchioloalveolar carcinoma: results of the first IASLC/ASCO consensus conference on bronchioloalveolar carcinoma. J. Thorac. Oncol. 1 (2006) S32-S36
15. Lane A.N., Fan T.W., and Higashi R.M. Isotopomer-based metabolomic analysis by NMR and mass spectrometry. Biophysical Tools for Biologists. Vol. 1. H. W. D. John J. Correia 84 (2008), Academic Press, San Diego 541-588
16. Lane A.N., Fan T.W.M., Higashi R.M., Tan J., Bousamra M., and Miller D.M. Prospects for clinical cancer metabolomics using stable isotope tracers. Exp. Molec. Pathol. 86 (2009) 165-173
17. Lu H.S., Forbes R.A., and Verma A. Hypoxia-inducible factor 1 activation by aerobic glycolysis implicates the Warburg effect in carcinogenesis. J. Biol. Chem. 277 (2002) 23111-23115
18. Pirozynski M. 100 years of lung cancer. Respir. Med. 100 (2006) 2073-2084
19. Raz D.J., He B.A., Rosell R., and Jablons D.M. Bronchioloalveolar carcinoma: a review. Clin. Lung Cancer 7 (2006) 313-322
20. Riely G.J., Pao W., Pham D.K., Li A.R., Rizvi N., Venkatraman E.S., Zakowski M.F., Kris M.G., Ladanyi M., and Miller V. Clinical course of patients with non-small cell lung cancer and epidermal growth factor receptor exon 19 and exon 21 mutations treated with gefitinib or erlotinib. Clin. Cancer Res. 12 (2006) 839-844
21. Sakuma Y., Matsukuma S., Yoshihara M., Nakamura Y., Noda K., Nakayama H., Kameda Y., Tsuchiya E., and Miyagi Y. Distinctive evaluation of nonmucinous and mucinous subtypes of bronchioloalveolar carcinomas in EGFR and K-ras gene-mutation analyses for Japanese lung adenocarcinomas - confirmation of the correlations with histologic subtypes and gene mutations. Am. J. Clin. Pathol. 128 (2007) 100-108
22. Wakelee H.A., Chang E.T., Gomez S.L., Keegan T.H., Feskanich D., Clarke C.A., Holmberg L., Yong L.C., Kolonel L.N., Gould M.K., and West D.W. Lung cancer incidence in never smokers. J. Clin. Oncol. 25 (2007) 472-478
23. Warburg O. On the origin of cancer cells. Science 123 (1956) 309-314